ReviewTherapeutics and clinical risk management2017
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.
Review in Therapeutics and clinical risk management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.Health science reports · 2026Article
- Bioinformatics and experimental validation of druggable targets in non-alcoholic fatty liver disease.Scientific reports · 2026Article
- Adapter-based allogeneic CAR T cells to overcome antigen escape in solid tumors.Frontiers in immunology · 2026Review
- Economic value of anti-CD20 therapies in multiple sclerosis: a systematic review of cost-effectiveness studies.Therapeutic advances in neurological disorders · 2026Review
- Case Report: Marburg variant of multiple sclerosis and review of its complicated treatment.Frontiers in immunology · 2026Review
- Data-driven hypothesis discovery from disease trajectories in multiple sclerosis.Frontiers in immunology · 2026Article
- Case Reports of Teprotumumab as Treatment for Monoclonal Antibody-Induced Thyroid Orbitopathy.Reports (MDPI) · 2025Article
- Article
- Sphingosine-1-Phosphate Modulation in Neurological Disorders: Insights from MS and Stroke.Brain sciences · 2025Review
- Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study.Neurology. Clinical practice · 2025Article
- Universal CAR cell therapy: Challenges and expanding applications.Translational oncology · 2025Review
- Management of alemtuzumab-induced Graves' disease in pregnancy: a case report and literature review.Frontiers in immunology · 2025Review
- The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.International journal of molecular sciences · 2024Review
- A case of relapsing anti-GBM disease secondary to alemtuzumab therapy.CEN case reports · 2024Article
- IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.Journal of neuropathology and experimental neurology · 2024Article
- SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.Therapeutic advances in neurological disorders · 2024Article
- Alemtuzumab-induced petechiae and epistaxis in a patient with relapsing-remitting multiple sclerosis: A case report.Clinical case reports · 2023Article
- Cellular and Molecular Evidence of Multiple Sclerosis Diagnosis and Treatment Challenges.Journal of clinical medicine · 2023Review
- Updates and advances in multiple sclerosis neurotherapeutics.Neurodegenerative disease management · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of disability showed significant reduction in the Phase II CAMMS223 and the Phase III clinical trials CARE MS I and CARE MS II. The data presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis confirmed these results. After completion of a 1-year treatment cycle, alemtuzumab showed a sustained effect. Although the efficacy of alemtuzumab has been widely proven, several severe adverse effects have been reported with its use. Infusion-associated reactions, increased risk of infections, and secondary autoimmunity have been associated with alemtuzumab. Autoimmune disease - mainly of the thyroid - has been reported. Immune thrombocytopenic purpura and autoimmune nephropathies have been observed less frequently. These adverse effects, given the short period of alemtuzumab marketing for relapsing remitting multiple sclerosis, require strict monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.